Recent progress in HIV vaccines inducing mucosal immune responses
In spite of several attempts over many years at developing a HIV vaccine based on classical strategies, none has convincingly succeeded to date. As HIV is transmitted primarily by the mucosal route, particularly through sexual intercourse, understanding antiviral immunity at mucosal sites is of majo...
Gespeichert in:
| Veröffentlicht in: | AIDS (London) 2014-07, Vol.28 (12), p.1701-1718 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1718 |
|---|---|
| container_issue | 12 |
| container_start_page | 1701 |
| container_title | AIDS (London) |
| container_volume | 28 |
| creator | Pavot, Vincent Rochereau, Nicolas Lawrence, Philip Girard, Marc P Genin, Christian Verrier, Bernard Paul, Stéphane |
| description | In spite of several attempts over many years at developing a HIV vaccine based on classical strategies, none has convincingly succeeded to date. As HIV is transmitted primarily by the mucosal route, particularly through sexual intercourse, understanding antiviral immunity at mucosal sites is of major importance. An ideal vaccine should elicit HIV-specific antibodies and mucosal CD8 cytotoxic T-lymphocyte (CTL) as a first line of defense at a very early stage of HIV infection, before the virus can disseminate into the secondary lymphoid organs in mucosal and systemic tissues. A primary focus of HIV preventive vaccine research is therefore the induction of protective immune responses in these crucial early stages of HIV infection. Numerous approaches are being studied in the field, including building upon the recent RV144 clinical trial. In this article, we will review current strategies and briefly discuss the use of adjuvants in designing HIV vaccines that induce mucosal immune responses. |
| doi_str_mv | 10.1097/QAD.0000000000000308 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_proquest_miscellaneous_1544740748</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1544740748</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5178-dcc3cc65b71ce6339b2acf835a4d62f8864a41089fae370bbefc5dc2d5d63f803</originalsourceid><addsrcrecordid>eNp90E1P7CAUBmBiNDpX_QfGdGPiXVShQKHLiXrvmExiNOqW0NNTp0rbEaYa_71MZvyIC9nwkYfD4SXkgNETRgt1ej0-P6HfB6d6g4yYUDyVUrFNMqJZXqQFV3SH_AnhMRpJtd4mO5mktChkPiLjGwTsFsnc9w8eQ0iaLplc3icvFqDpcLmvhrh6SNoB-mBd0rTt0GES8bzvAoY9slVbF3B_Pe-Su38Xt2eTdHr1__JsPE1BMqXTCoAD5LJUDDDnvCgzC7Xm0ooqz2qtc2EFo7qoLcaOyxJrkBVklaxyXmvKd8nfVd2ZdWbum9b6N9PbxkzGU7M8o6xgjGfshUV7vLLxW88DhoVpmwDonO2wH4JhUgglqBI6UrGi4PsQPNaftRk1y6BNDNr8DDpeO1y_MJQtVp-XPpKN4GgNbADram87aMKX0ypjWi2dXrnX3i3Qhyc3vKI3M7RuMfu9h3dJGpWL</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1544740748</pqid></control><display><type>article</type><title>Recent progress in HIV vaccines inducing mucosal immune responses</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Pavot, Vincent ; Rochereau, Nicolas ; Lawrence, Philip ; Girard, Marc P ; Genin, Christian ; Verrier, Bernard ; Paul, Stéphane</creator><creatorcontrib>Pavot, Vincent ; Rochereau, Nicolas ; Lawrence, Philip ; Girard, Marc P ; Genin, Christian ; Verrier, Bernard ; Paul, Stéphane</creatorcontrib><description>In spite of several attempts over many years at developing a HIV vaccine based on classical strategies, none has convincingly succeeded to date. As HIV is transmitted primarily by the mucosal route, particularly through sexual intercourse, understanding antiviral immunity at mucosal sites is of major importance. An ideal vaccine should elicit HIV-specific antibodies and mucosal CD8 cytotoxic T-lymphocyte (CTL) as a first line of defense at a very early stage of HIV infection, before the virus can disseminate into the secondary lymphoid organs in mucosal and systemic tissues. A primary focus of HIV preventive vaccine research is therefore the induction of protective immune responses in these crucial early stages of HIV infection. Numerous approaches are being studied in the field, including building upon the recent RV144 clinical trial. In this article, we will review current strategies and briefly discuss the use of adjuvants in designing HIV vaccines that induce mucosal immune responses.</description><identifier>ISSN: 0269-9370</identifier><identifier>EISSN: 1473-5571</identifier><identifier>DOI: 10.1097/QAD.0000000000000308</identifier><identifier>PMID: 25009956</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins, Inc</publisher><subject>Adjuvants, Immunologic - administration & dosage ; AIDS Vaccines - immunology ; AIDS Vaccines - isolation & purification ; AIDS/HIV ; Bacteriology ; Biological and medical sciences ; Drug Discovery - trends ; HIV Infections - immunology ; HIV Infections - prevention & control ; Human viral diseases ; Humans ; Immunity, Mucosal ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunology ; Immunopathology ; Infectious diseases ; Life Sciences ; Medical sciences ; Microbiology and Parasitology ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Virology</subject><ispartof>AIDS (London), 2014-07, Vol.28 (12), p.1701-1718</ispartof><rights>2014 Lippincott Williams & Wilkins, Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5178-dcc3cc65b71ce6339b2acf835a4d62f8864a41089fae370bbefc5dc2d5d63f803</citedby><cites>FETCH-LOGICAL-c5178-dcc3cc65b71ce6339b2acf835a4d62f8864a41089fae370bbefc5dc2d5d63f803</cites><orcidid>0000-0002-7637-045X ; 0000-0002-8830-4273</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28721876$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25009956$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-01911321$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Pavot, Vincent</creatorcontrib><creatorcontrib>Rochereau, Nicolas</creatorcontrib><creatorcontrib>Lawrence, Philip</creatorcontrib><creatorcontrib>Girard, Marc P</creatorcontrib><creatorcontrib>Genin, Christian</creatorcontrib><creatorcontrib>Verrier, Bernard</creatorcontrib><creatorcontrib>Paul, Stéphane</creatorcontrib><title>Recent progress in HIV vaccines inducing mucosal immune responses</title><title>AIDS (London)</title><addtitle>AIDS</addtitle><description>In spite of several attempts over many years at developing a HIV vaccine based on classical strategies, none has convincingly succeeded to date. As HIV is transmitted primarily by the mucosal route, particularly through sexual intercourse, understanding antiviral immunity at mucosal sites is of major importance. An ideal vaccine should elicit HIV-specific antibodies and mucosal CD8 cytotoxic T-lymphocyte (CTL) as a first line of defense at a very early stage of HIV infection, before the virus can disseminate into the secondary lymphoid organs in mucosal and systemic tissues. A primary focus of HIV preventive vaccine research is therefore the induction of protective immune responses in these crucial early stages of HIV infection. Numerous approaches are being studied in the field, including building upon the recent RV144 clinical trial. In this article, we will review current strategies and briefly discuss the use of adjuvants in designing HIV vaccines that induce mucosal immune responses.</description><subject>Adjuvants, Immunologic - administration & dosage</subject><subject>AIDS Vaccines - immunology</subject><subject>AIDS Vaccines - isolation & purification</subject><subject>AIDS/HIV</subject><subject>Bacteriology</subject><subject>Biological and medical sciences</subject><subject>Drug Discovery - trends</subject><subject>HIV Infections - immunology</subject><subject>HIV Infections - prevention & control</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunity, Mucosal</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunology</subject><subject>Immunopathology</subject><subject>Infectious diseases</subject><subject>Life Sciences</subject><subject>Medical sciences</subject><subject>Microbiology and Parasitology</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Virology</subject><issn>0269-9370</issn><issn>1473-5571</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90E1P7CAUBmBiNDpX_QfGdGPiXVShQKHLiXrvmExiNOqW0NNTp0rbEaYa_71MZvyIC9nwkYfD4SXkgNETRgt1ej0-P6HfB6d6g4yYUDyVUrFNMqJZXqQFV3SH_AnhMRpJtd4mO5mktChkPiLjGwTsFsnc9w8eQ0iaLplc3icvFqDpcLmvhrh6SNoB-mBd0rTt0GES8bzvAoY9slVbF3B_Pe-Su38Xt2eTdHr1__JsPE1BMqXTCoAD5LJUDDDnvCgzC7Xm0ooqz2qtc2EFo7qoLcaOyxJrkBVklaxyXmvKd8nfVd2ZdWbum9b6N9PbxkzGU7M8o6xgjGfshUV7vLLxW88DhoVpmwDonO2wH4JhUgglqBI6UrGi4PsQPNaftRk1y6BNDNr8DDpeO1y_MJQtVp-XPpKN4GgNbADram87aMKX0ypjWi2dXrnX3i3Qhyc3vKI3M7RuMfu9h3dJGpWL</recordid><startdate>20140731</startdate><enddate>20140731</enddate><creator>Pavot, Vincent</creator><creator>Rochereau, Nicolas</creator><creator>Lawrence, Philip</creator><creator>Girard, Marc P</creator><creator>Genin, Christian</creator><creator>Verrier, Bernard</creator><creator>Paul, Stéphane</creator><general>Lippincott Williams & Wilkins, Inc</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-7637-045X</orcidid><orcidid>https://orcid.org/0000-0002-8830-4273</orcidid></search><sort><creationdate>20140731</creationdate><title>Recent progress in HIV vaccines inducing mucosal immune responses</title><author>Pavot, Vincent ; Rochereau, Nicolas ; Lawrence, Philip ; Girard, Marc P ; Genin, Christian ; Verrier, Bernard ; Paul, Stéphane</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5178-dcc3cc65b71ce6339b2acf835a4d62f8864a41089fae370bbefc5dc2d5d63f803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adjuvants, Immunologic - administration & dosage</topic><topic>AIDS Vaccines - immunology</topic><topic>AIDS Vaccines - isolation & purification</topic><topic>AIDS/HIV</topic><topic>Bacteriology</topic><topic>Biological and medical sciences</topic><topic>Drug Discovery - trends</topic><topic>HIV Infections - immunology</topic><topic>HIV Infections - prevention & control</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunity, Mucosal</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunology</topic><topic>Immunopathology</topic><topic>Infectious diseases</topic><topic>Life Sciences</topic><topic>Medical sciences</topic><topic>Microbiology and Parasitology</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pavot, Vincent</creatorcontrib><creatorcontrib>Rochereau, Nicolas</creatorcontrib><creatorcontrib>Lawrence, Philip</creatorcontrib><creatorcontrib>Girard, Marc P</creatorcontrib><creatorcontrib>Genin, Christian</creatorcontrib><creatorcontrib>Verrier, Bernard</creatorcontrib><creatorcontrib>Paul, Stéphane</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>AIDS (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pavot, Vincent</au><au>Rochereau, Nicolas</au><au>Lawrence, Philip</au><au>Girard, Marc P</au><au>Genin, Christian</au><au>Verrier, Bernard</au><au>Paul, Stéphane</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recent progress in HIV vaccines inducing mucosal immune responses</atitle><jtitle>AIDS (London)</jtitle><addtitle>AIDS</addtitle><date>2014-07-31</date><risdate>2014</risdate><volume>28</volume><issue>12</issue><spage>1701</spage><epage>1718</epage><pages>1701-1718</pages><issn>0269-9370</issn><eissn>1473-5571</eissn><abstract>In spite of several attempts over many years at developing a HIV vaccine based on classical strategies, none has convincingly succeeded to date. As HIV is transmitted primarily by the mucosal route, particularly through sexual intercourse, understanding antiviral immunity at mucosal sites is of major importance. An ideal vaccine should elicit HIV-specific antibodies and mucosal CD8 cytotoxic T-lymphocyte (CTL) as a first line of defense at a very early stage of HIV infection, before the virus can disseminate into the secondary lymphoid organs in mucosal and systemic tissues. A primary focus of HIV preventive vaccine research is therefore the induction of protective immune responses in these crucial early stages of HIV infection. Numerous approaches are being studied in the field, including building upon the recent RV144 clinical trial. In this article, we will review current strategies and briefly discuss the use of adjuvants in designing HIV vaccines that induce mucosal immune responses.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>25009956</pmid><doi>10.1097/QAD.0000000000000308</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0002-7637-045X</orcidid><orcidid>https://orcid.org/0000-0002-8830-4273</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-9370 |
| ispartof | AIDS (London), 2014-07, Vol.28 (12), p.1701-1718 |
| issn | 0269-9370 1473-5571 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1544740748 |
| source | MEDLINE; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Adjuvants, Immunologic - administration & dosage AIDS Vaccines - immunology AIDS Vaccines - isolation & purification AIDS/HIV Bacteriology Biological and medical sciences Drug Discovery - trends HIV Infections - immunology HIV Infections - prevention & control Human viral diseases Humans Immunity, Mucosal Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunology Immunopathology Infectious diseases Life Sciences Medical sciences Microbiology and Parasitology Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Virology |
| title | Recent progress in HIV vaccines inducing mucosal immune responses |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T00%3A06%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recent%20progress%20in%20HIV%20vaccines%20inducing%20mucosal%20immune%20responses&rft.jtitle=AIDS%20(London)&rft.au=Pavot,%20Vincent&rft.date=2014-07-31&rft.volume=28&rft.issue=12&rft.spage=1701&rft.epage=1718&rft.pages=1701-1718&rft.issn=0269-9370&rft.eissn=1473-5571&rft_id=info:doi/10.1097/QAD.0000000000000308&rft_dat=%3Cproquest_hal_p%3E1544740748%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1544740748&rft_id=info:pmid/25009956&rfr_iscdi=true |